Anzeige
Mehr »
Lynx Broker
Login
Samstag, 21.09.2019 Börsentäglich über 12.000 News von 610 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1423S ISIN: ES0169501030 Ticker-Symbol: PMR 
Stuttgart
20.09.19
15:36 Uhr
1,829 Euro
-0,060
-3,18 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PHARMA MAR SA Chart 1 Jahr
5-Tage-Chart
PHARMA MAR SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,823
1,869
20.09.
1,822
1,862
20.09.

Aktuelle News zur PHARMAMAR Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.08.PHARMA MAR, S.A.: Pharma Mar and Janssen have entered into a new licensing agreement for Yondelis in US and a ...5
19.08.PHARMA MAR, S.A.: Pharma Mar will submit New Drug Application for lurbinectedin under accelerated approval in small ...15
29.07.PHARMA MAR, S.A.: o The Company sends press release regarding first half 2019 results.6
PHARMAMAR Aktien jetzt im kostenlosen Demokonto handeln!
29.07.PHARMA MAR, S.A.: The Company reports the resignation and appointment of the new Secretary of the Board of Directors ...4
03.07.PHARMA MAR, S.A.: The Company reports details of the operations of the Liquidity Agreement between 01/04/2019 ...7
28.06.PHARMA MAR, S.A.: The Company reports the formalization and execution of the closing of the sale of the shares ...2
26.06.PHARMA MAR, S.A.: The General Shareholders Meeting has authorized the sale of the shares of its subsidiary Zelnova ...3
26.06.PHARMA MAR, S.A.: It is reported that all proposed resolutions submitted by the Board to the General Shareholders' ...1
26.06.PHARMA MAR, S.A.: The Company reports changes in the composition of its Board of Directors and its Committees3
26.06.PHARMA MAR, S.A.: Attached is a copy of the presentation to shareholders to be made at the General Shareholders' ...1
12.06.PHARMA MAR, S.A.: The Executive Committee of Pharma Mar, S.A. has decided to implement the Free of Charge Stock ...5
03.06.PHARMA MAR, S.A.: Conference call related to the Zepsyre results recently presented at ASCO by Dr. Paz Ares.4
03.06.BRIEF-Pharma Mar Says Lurbinectedin Achieves Positive Results In Phase II Trial For Treatment Of Small Cell Lung Cancer6
03.06.PHARMA MAR, S.A.: Information about the results presented at the annual meeting of the American Society of Clinical ...4
23.05.PHARMA MAR, S.A.: The Company announces decision of the Board of Directors to call the Ordinary General Shareholders' ...6
23.05.PHARMA MAR, S.A.: The Board of Directors of Pharma Mar has approved the signing of a contract for the sale of ...2
16.05.PHARMA MAR, S.A.: Abstract information to be presented at the annual meeting of the American Society of Clinical ...2
15.05.PHARMA MAR, S.A.: American Society of Clinical Oncology (ASCO) selects a lurbinectedin abstract for Best of ASCO" ...2
26.04.PHARMA MAR, S.A.: The Company sends press release regarding the Q1 2019 results11
26.04.PHARMA MAR, S.A.: Axesor ratifies the rating of Pharma Mar, S.A. and its outlook as stable.6
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,1